APA (7th ed.) Citation

Lennox, A. L., Huang, F., González‐Sales, M., Wan, Y., Sun, L., Berry, T., . . . Morcos, P. N. (2025). No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower‐Risk Myelodysplastic Syndromes. CTS: Clinical & Translational Science, 18(12), 1. https://doi.org/10.1111/cts.70431

Chicago Style (17th ed.) Citation

Lennox, Ashley L., Fei Huang, Mario González‐Sales, Ying Wan, Libo Sun, Tymara Berry, Faye Feller, and Peter N. Morcos. "No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower‐Risk Myelodysplastic Syndromes." CTS: Clinical & Translational Science 18, no. 12 (2025): 1. https://doi.org/10.1111/cts.70431.

MLA (9th ed.) Citation

Lennox, Ashley L., et al. "No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower‐Risk Myelodysplastic Syndromes." CTS: Clinical & Translational Science, vol. 18, no. 12, 2025, p. 1, https://doi.org/10.1111/cts.70431.